Monday, September 15, 2025 9/15/2025

Distinct Pathways of VPF/VEGF Receptors

Award Number: R01HL140411
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/08/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Distinct Pathways of VPF/VEGF Receptors - Project Summary The long-term objective of this application is to understand the molecular pathways of myocardial infraction (MI)- mediated cardiac fibrosis and eventually heart failure. In our last grant cycle, we elucidated thoroughly the role of Neuropilin-1 (NRP1), a multi-ligand receptor/adaptor and mediator of different signaling pathways including TGFβ, in MI-induced cardiac pathogenesis, in particular fibrosis, and inflammation. Our preliminary data suggest that conditional knockdown of NRP1 in the adult mice, either in cardiomyocytes (CM) or in endothelial cells (EC) resulted varied phenotypes following cardiac injury (MI). In addition, our preliminary data from the single-nucleus RNA sequencing (snRNA seq) using the cardiac tissues in a cell-specific manner and revealed marked changes in gene expression patterns of key genes previously known to be associated with inflammation, cardiac hypertrophy, fibrosis. In addition, we revealed microRNA (miR30s) showed differentially expressed in ECNRP1-/- vs. CMNRP1-/- cells that correlated with HF genes. Hence, the scientific premise of this proposal is to reveal the mechanistic role of divergent NRP1 spatiotemporal signaling in MI pathogenesis, and eventually to develop new therapeutic targets and strategies to overcome progressive cardiac dysfunctions and overall heart failure. In this regard, we will examine the spatiotemporal influence of NRP1 pathways for cardiac fibrosis following MI injury as well as define the tissue-specific role of microRNAs regulated by NRP1 pathways on MI-induced fibrosis. Finally, we will develop new therapeutic approaches to overcome cardio fibrosis following MI injury combining novel NRP1 inhibitor (NRP1i) using novel targeted liposomal formulations. The current application is a multi- disciplinary approach to reveal the spatiotemporal role of NRP1 in cardiac fibrosis/remodeling and identify new targets to develop novel therapies to overcome one of the most common myocardial pathologies, which is an unmet clinical need.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $653,379 )
2025	2025	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	6	7/23/2025	NON-COMPETING CONTINUATION	$653,379
														Subtotal = $653,379

Issue Date FY: 2024 ( Subtotal = $667,504 )
2024	2024	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	5	3/13/2024	COMPETING CONTINUATION	$667,504
														Subtotal = $667,504

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	4	9/27/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $512,279 )
2021	2021	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	001	4	5/15/2021	NON-COMPETING CONTINUATION	$51,228
2021	2021	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	4	12/10/2020	NON-COMPETING CONTINUATION	$461,051
														Subtotal = $512,279

Issue Date FY: 2020 ( Subtotal = $512,279 )
2020	2020	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	001	3	3/7/2020	NON-COMPETING CONTINUATION	$25,613
2020	2020	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	3	12/11/2019	NON-COMPETING CONTINUATION	$486,666
														Subtotal = $512,279

Issue Date FY: 2019 ( Subtotal = $542,279 )
2019	2019	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	2	12/21/2018	NON-COMPETING CONTINUATION	$542,279
														Subtotal = $542,279

Issue Date FY: 2018 ( Subtotal = $512,279 )
2018	2018	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	1	12/8/2017	NEW	$512,279
														Subtotal = $512,279

Grand Total All Awards = $3,399,999

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Distinct Pathways of VPF/VEGF Receptors

Award Number: R01HL140411

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/08/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer